Acarix announces the last patient included in Dan-NICAD
II study


After the inclusion of 1726 patients, Acarix announces that the last patient has been included in Dan-NICAD II, a study of noninvasive diagnostic testing in patients with suspected Coronary Artery Disease (CAD).










About Acarix
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.